Andy Im Hoepelman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1374426/publications.pdf

Version: 2024-02-01

20 papers 396 citations

11 h-index 18 g-index

20 all docs

20 docs citations

times ranked

20

730 citing authors

#	Article	IF	CITATIONS
1	Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. Journal of Medical Virology, 2009, 81, 441-445.	5.0	70
2	Accumulation of Drug Resistance and Loss of Therapeutic Options Precede Commonly Used Criteria for Treatment Failure in HIV-1 Subtype-C-Infected Patients. Antiviral Therapy, 2012, 17, 377-386.	1.0	50
3	Risk of recurrent acute lower urinary tract infections and prescription pattern of antibiotics in women with and without diabetes in primary care. Family Practice, 2010, 27, 379-385.	1.9	49
4	Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in a Dutch family: evidence for a TNFRSF1A mutation with reduced penetrance. European Journal of Human Genetics, 2001, 9, 63-66.	2.8	44
5	The Skn7 response regulator of Cryptococcus neoformansis involved in oxidative stress signalling and augments intracellular survival in endothelium. FEMS Yeast Research, 2006, 6, 652-661.	2.3	40
6	Presence of occult HBV, but near absence of active HBV and HCV infections in people infected with HIV in rural South Africa. Journal of Medical Virology, 2011, 83, 929-934.	5.0	27
7	Virulence factors of Escherichia coli isolated from urine of diabetic women with asymptomatic bacteriuria: correlation with clinical characteristics. Antonie Van Leeuwenhoek, 2001, 80, 119-127.	1.7	22
8	Use of the moving epidemic method (MEM) to assess national surveillance data for respiratory syncytial virus (RSV) in the Netherlands, 2005 to 2017. Eurosurveillance, 2019, 24, .	7.0	21
9	Development of sensitive dd <scp>PCR</scp> assays to reliably quantify the proviral <scp>DNA</scp> reservoir in all common circulating <scp>HIV</scp> subtypes and recombinant forms. Journal of the International AIDS Society, 2018, 21, e25185.	3.0	16
10	Pegylated interferon- $\hat{l}\pm$ monotherapy leads to low response rates in HIV-infected patients with acute hepatitis C. Antiviral Therapy, 2011, 16, 979-988.	1.0	11
11	The MOTIVATE trials: maraviroc therapy in antiretroviral treatment-experienced HIV-1-infected patients. Expert Review of Anti-Infective Therapy, 2012, 10, 1241-1247.	4.4	11
12	Abacavir/Lamivudine/Zidovudine Maintenance After Standard Induction in Antiretroviral Therapy-Na $ ilde{A}$ -ve Patients: FREE Randomized Trial Interim Results. AIDS Patient Care and STDs, 2010, 24, 361-366.	2.5	9
13	History taking and leukocyturia predict the presence of asymptomatic bacteriuria in women with diabetes mellitus. European Journal of Epidemiology, 2004, 19, 1021-1027.	5.7	7
14	The effect of switching protease inhibitors to raltegravir on endothelial function, in HIV-infected patients. HIV Clinical Trials, 2018, 19, 75-83.	2.0	6
15	Impact of transient elastography on clinical decision-making in patients with chronic viral hepatitis. Scandinavian Journal of Gastroenterology, 2013, 48, 1074-1081.	1.5	4
16	Peginterferon monotherapy for the treatment of acute hepatitis C in HIV-coinfected patients. Aids, 2008, 22, 1381-1382.	2.2	3
17	Telbivudine Exerts no Antiviral Activity against HIV-1 <i>In Vitro</i> and in Humans. Antiviral Therapy, 2011, 16, 1123-1130.	1.0	3
18	Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting. Antiviral Therapy, 2013, 18, 615-622.	1.0	3

#	Article	lF	CITATIONS
19	Peripheral T-cell apoptosis is not differentially affected by antiretroviral regimens in HIV-infected patients. Antiviral Therapy, 2013, 18, 1021-1025.	1.0	0
20	The influences of antiviral therapy on T-cell function in adult patients with chronic hepatitis B. Future Virology, 2014, 9, 913-920.	1.8	0